Mechanism of Action
Membrane Disruption
Melittin adopts an amphipathic alpha-helical conformation in membrane environments, inserting into lipid bilayers. At low concentrations it forms transient pores (toroidal pore model); at higher concentrations it causes carpet-like membrane solubilization. This mechanism disrupts bacterial, fungal, viral envelopes, and mammalian cell membranes without selectivity, explaining both its broad antimicrobial activity and its hemolytic toxicity.
Intracellular Signaling
Beyond membrane disruption, melittin activates phospholipase A2 (PLA2) indirectly via membrane perturbation, releasing arachidonic acid and initiating prostaglandin/leukotriene synthesis. It inhibits NF-kB and downstream pro-inflammatory cytokines in immune cells. At sub-lytic concentrations, melittin can modulate cell signaling without causing immediate cell death.
Research Summary
Anti-Cancer Activity
PreclinicalMelittin shows cytotoxic activity against numerous cancer cell lines including breast, prostate, lung, and hepatocellular carcinoma. Nano-encapsulated melittin (lipid-coated nanoparticles) selectively targets tumor vasculature. Melittin-drug conjugates (e.g., melittin-paclitaxel) show synergistic anticancer effects in murine tumor models.
Antiviral Activity
PreclinicalMelittin disrupts viral envelopes, showing activity against HIV, HSV, influenza, and HPV in cell culture. Nano-particle formulations sequestering melittin until HIV contact have been developed to maintain antiviral activity while reducing systemic toxicity.
Anti-Inflammatory (Bee Venom Therapy)
Limited ClinicalBee venom acupuncture (BVA) using dilute bee venom containing melittin shows anti-inflammatory effects in arthritis and Parkinson's disease in pilot clinical trials, involving NF-kB inhibition and regulatory T cell induction.
Calculate your Melittin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anticancer cytotoxicity (in vitro) | 1-20 uM | Single time-point (24-72h) | In vitro cell culture |
| Antimicrobial MIC | 0.5-32 ug/mL | Single plate read | In vitro broth microdilution |
| Bee venom therapy (dilute) | 0.1-1 mg/mL diluted venom | Acupuncture point injection | Intradermal/subcutaneous |
Systemic melittin is too hemolytic for IV use. Research focuses on encapsulated formulations.
Interactions
Safety Profile
Melittin is acutely hemolytic at systemic doses, precluding IV administration. Local injection (bee sting, BVA) causes pain, local inflammation, and edema. Systemic envenomation in sensitive individuals causes anaphylaxis and multi-organ failure. No approved melittin product exists.
References
- [1]Habermann E. Bee and wasp venoms. Science. 1972;177(4046):314-322.
- [2]Leuschner C, Bhatt DL. Melittin potently inhibits tumor growth and metastasis. Oncogene. 1996;13(12):2621-2625.
- [3]Hood JD, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404-2407.